Micrus Endovascular Corp

Micrus Endovascular — Merger or Acquisition (July 2010)

18 slides from Micrus Endovascular's merger presentation, Jul 13, 2010

  1. Slide 1: Schedule 14A - Micrus Endovascular Corporation / Johnson & Johnson

    Slide 1: Schedule 14A - Micrus Endovascular Corporation / Johnson & Johnson

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __) Filed by the Registrant o Filed by

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    The following presentation was delivered by representatives of Johnson & Johnson to employees of Micrus Endovascular Corporation on July 12, 2010. Forward Looking Statements This communication includes “forward-looking statements”, within the meaning of the Private Securities Litigation Reform Act o

  3. Slide 3: Introduction to Codman: A Global Medical Device Company

    Slide 3: Introduction to Codman: A Global Medical Device Company

    INTRODUCTION TO CODMAN: A Global Medical Device Company Leading the Evolution in Neuroscience July, 2010

  4. Slide 4: Our Mission

    Slide 4: Our Mission

    Our Mission: To Improve the quality of life in many more patients worldwide by developing innovative solutions across a broad spectrum of neurological conditions

  5. Slide 5: J&J's Global Presence, Diversified Business

    Slide 5: J&J's Global Presence, Diversified Business

    J&J’s Global Presence Diversified Business • One of the World’s Largest Medical Devices Health Care Companies & Diagnostics 38% Consumer • 115,000 Employees 26% • 250 Operating Companies In $23.6B 57 Countries $15.8B • Selling Products in Over 175 Countries $22.5B Pharmaceutical 36%

  6. Slide 6: Our Credo

    Slide 6: Our Credo

    “We believe our first responsibility is to doctors, nurses and patients…” “We are also responsible to our employees…” “We are also responsible to the communities we serve…” “Our final responsibility is to our stockholders…” Our Credo We believe our first responsibility is to the doctors, nurses and

  7. Slide 7: The DePuy Companies of Johnson & Johnson

    Slide 7: The DePuy Companies of Johnson & Johnson

    The DePuy Companies of Johnson & Johnson Neurological and Joint Neurovascular Reconstruction Treatment and Trauma Sports Medicine and Minimally Invasive Joint Therapies

  8. Slide 8: never stop moving

    Slide 8: never stop moving

    6 never stop moving™ Meaningful innovation that makes a difference Shared knowledge that advances understanding Caring touch that puts patients first

  9. Slide 9: Codman key facts: sold in over 50 countries, 500+ employees

    Slide 9: Codman key facts: sold in over 50 countries, 500+ employees

    • Products sold in over 50 countries • Global workforce of over 500 people • Worldwide headquarters: • Raynham, MA • Manufacturing locations: • Massachusetts • Germany • Switzerland • Mexico 7 7

  10. Slide 10: Codman & Shurtleff is Creating a Global Presence in Neuroscience

    Slide 10: Codman & Shurtleff is Creating a Global Presence in Neuroscience

    Codman & Shurtleff, Inc. is Creating a Global Presence in Neuroscience • A Total Neuroscience Company with a broad product line • From a Foundation with Neurosurgeons worldwide • Integrated Cordis neurovascular (CNV) business into Codman in 2009 • Launched MEDSTREAM neuromodulation drug pump in 2009

  11. Slide 11: Vast Unmet Need Remains in Treating Neurological Disorders

    Slide 11: Vast Unmet Need Remains in Treating Neurological Disorders

    Vast Unmet Need Remains in Treating Neurological Disorders Each year, there are over 30 million newly diagnosed patients worldwide with neurological disease Ø Worldwide, 1-in-5, or 1.7billion people, suffer from neurological ** diseases, yet less than 1-in-5 of these people are treated § In the US,

  12. Slide 12: We Offer an Industry-leading Product Portfolio

    Slide 12: We Offer an Industry-leading Product Portfolio

    We Offer an Industry-leading Product Portfolio Major Conditions / Diseases Products • Aneurysms Access & Neurovascular • Arteriovenous Malformation (AVM’s) Treat Vascular reconstructive devices, embolics and access products Operative • Tumors Neurosurgery • Cerebrovascular Access & Neurodisposables,

  13. Slide 13: We are investing in Transformational Technologies

    Slide 13: We are investing in Transformational Technologies

    We are investing in Transformational Technologies* Drug Delivery Build on MEDSTREAM pump with new compounds for neurologic Neuromodulation conditions Neurostimulators SNS Selective nerve stimulation for under-treated diseases, including epilepsy, depression, stroke Biologics Placental stem cell focu

  14. Slide 14: Competitive Advantages

    Slide 14: Competitive Advantages

    Competitive Advantages ENTERPRISE Stent Platform Global Footprint & Alignment World-class Prof Ed Capabilities Codman: Total Neurosciences Approach CNV Strategic Framework Education to Expand Globally Innovation to Improve Patient Care Growth Strategies Evidence to Drive Adoption & Reimbursement Att

  15. Slide 15: DePuy Institute and professional education

    Slide 15: DePuy Institute and professional education

    DePuy • Hydrocephalus Institute, LLC • Neurovascular State-of-the-art 70,000 sq ft facility • Neuro Critical Care • Raising Awareness • NPH Patient Campaign • NPH Referral Development Addressing the unmet educational and clinical needs in a rapidly changing and expanding health care environment for

  16. Slide 16: Our Commitment

    Slide 16: Our Commitment

    Our Commitment Strengthen Global Presence in Neuroscience Offer an Industry-leading Product Portfolio Advance Breakthrough Future Therapies

  17. Slide 17: Forward Looking Statements

    Slide 17: Forward Looking Statements

    Forward Looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties mat

  18. Slide 18: Additional Information About the Proposed Transaction and Where to Find It

    Slide 18: Additional Information About the Proposed Transaction and Where to Find It

    Additional Information About the Proposed Transaction and Where to Find It In connection with the proposed transaction, Micrus Endovascular Corporation intends to file a definitive proxy statement and other relevant materials with the Securities and Exchange Commission (the “SEC”). Before making any

Source: SEC EDGAR · DFAN14A filed Jul 13, 2010

More decks from Micrus Endovascular Corp